Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context.
The aim of this study was to assess the effects of selective blockade of the delta (DOP) or mu (MOP) opioid receptors on alcohol-seeking induced by discrete cues and context. In Experiment 1, rats were trained to self-administer alcohol in an environment with distinct sensory properties. After extinction in a different context with separate sensory properties, rats were tested for context-induced renewal in the original context following treatment with the DOP receptor antagonist naltrindole (0-15 mg/kg, i.p.) or the MOP receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2) (CTOP) (0-3 microg/4 microL, i.c.v.). In Experiment 2, reinstatement was tested with the presentation of a discrete light + tone cue previously associated with alcohol delivery, following extinction without the cue. The effects of naltrindole (0-5 mg/kg, i.p.) or CTOP (0-3 microg/4 microL, i.c.v.) were assessed. For context-induced renewal, 7.5 mg/kg naltrindole reduced responding without affecting locomotor activity. Both doses of CTOP attenuated responding in the first 15 min of the renewal test session; however, total responses did not differ at the end of the session. For discrete-cue-induced reinstatement, 1 and 5 mg/kg naltrindole attenuated responding but CTOP had no effect. We conclude that whereas DOP receptors mediate alcohol-seeking induced by discrete cues and context, MOP receptors may play a modest role only in context-induced renewal. These findings point to a differential involvement of opioid receptor subtypes in the effects of different kinds of conditioned stimuli on alcohol-seeking and support a more prominent role for DOP receptors.
Marinelli
Peter W
PW
Department of Neuroscience, Neurobiology of Alcohol Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada. Peter_marinelli@camh.net
Funk
Douglas
D
Harding
Stephen
S
Li
Zhaoxia
Z
Juzytsch
Walter
W
Lê
A D
AD
D000704:Analysis of Variance; D000818:Animals; D016739:Behavior, Addictive; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology*; D003463:Cues; D004305:Dose-Response Relationship, Drug; D004777:Environment; D000431:Ethanol / Q000008:administration & dosage*; D005108:Extinction, Psychological / Q000187:drug effects / Q000502:physiology; D007276:Injections, Intraventricular; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017465:Receptors, Opioid, delta / Q000502:physiology*; D017450:Receptors, Opioid, mu / Q000502:physiology*; D012646:Self Administration; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology
D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; C049352:phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide; D000431:Ethanol; D013004:Somatostatin; D009271:Naltrexone; C055382:naltrindole
Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50
1347943
J Pharmacol Exp Ther. 1993 Sep;266(3):1236-46
7690399
Neuropsychopharmacology. 2008 May;33(6):1402-12
17653111
Neuropharmacology. 2008 Oct;55(5):712-6
18588903
Alcohol. 2006 Feb;38(2):81-8
16839854
Neuropsychopharmacology. 2002 Dec;27(6):1006-15
12464457
Pharmacol Biochem Behav. 1998 Mar;59(3):627-35
9512064
Brain Res. 1993 Dec 10;630(1-2):330-2
8118700
Neuropsychopharmacology. 1999 Sep;21(3):435-44
10457541
Psychopharmacology (Berl). 1998 Jan;135(2):169-74
9497022
Psychopharmacology (Berl). 2003 Jul;168(1-2):222-228
12719962
Neuropsychopharmacology. 2002 Sep;27(3):391-9
12225696
Eur J Pharmacol. 1996 May 23;304(1-3):7-13
8813578
Behav Neurosci. 2002 Feb;116(1):169-73
11895178
Psychopharmacology (Berl). 2005 Sep;181(2):197-206
15830224
J Neurosci. 2007 Nov 14;27(46):12655-63
18003845
Pharmacol Biochem Behav. 1993 Jul;45(3):697-701
8101382
Psychopharmacology (Berl). 1991;103(4):467-72
1648247
Biol Psychiatry. 2007 Apr 15;61(8):979-89
17098214
Eur J Neurosci. 2007 Nov;26(10):2815-23
18001278
Psychopharmacology (Berl). 1995 Jul;120(2):177-85
7480550
Pharmacol Biochem Behav. 1995 Sep;52(1):153-9
7501658
Alcohol Clin Exp Res. 1999 Aug;23(8):1386-94
10470982
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3233-43
18640922
Neuropsychopharmacology. 1999 May;20(5):471-9
10192827
J Neurosci. 2004 Nov 24;24(47):10726-30
15564590
Neuropsychopharmacology. 2005 Feb;30(2):296-309
15483559
Regul Pept. 1995 Oct 20;59(2):183-92
8584753
Psychopharmacology (Berl). 2003 Jul;168(1-2):208-215
12664190
J Pharmacol Exp Ther. 1989 Jan;248(1):73-80
2563293
Psychopharmacology (Berl). 1999 Nov;147(1):81-9
10591872
Brain Res. 1995 Aug 28;690(1):112-6
7496796
Alcohol Clin Exp Res. 2001 Jan;25(1):25-33
11198711
Behav Brain Res. 2006 Feb 15;167(1):150-5
16256214
Psychopharmacology (Berl). 2008 Oct;200(3):357-65
18587561
J Neurosci. 2002 Sep 15;22(18):7856-61
12223538
J Stud Alcohol. 1990 Nov;51(6):494-9
2270057
J Abnorm Psychol. 2000 Nov;109(4):738-42
11195999
Neuroscience. 2006;139(3):877-87
16516392
Eur J Pharmacol. 1988 Jan 27;146(1):185-6
2832195